No profile data available.
Pliant Therapeutics, Inc. (PLRX) is a healthcare company in the lung treatment pharmaceuticals industry, based in South San Francisco, United States, with about 49 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$149.34 million. Its market capitalization was $63.16 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Pliant Therapeutics reported $0 in revenue for fiscal year 2025.
$63.16 million as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Upstream Bio, Inc. (UPB), Sionna Therapeutics, Inc. (SION), Rein Therapeutics Inc. (RNTX), Edesa Biotech, Inc. (EDSA).